New drug switch may stop shakes in transplant patients
NCT ID NCT03769298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether switching from standard tacrolimus to a once-daily version (Envarsus XR) can reduce tremors in people who received a pancreas-kidney transplant. Twenty adults who have had a transplant and developed tremors will take the new drug and be monitored for changes in tremor severity and quality of life. The goal is to see if this switch improves symptoms while keeping the transplanted organs healthy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Envarsus XR (tacrolimus)
- What this could lead to
- If successful, this could offer a way to reduce bothersome tremors and improve daily life for pancreas-kidney transplant patients without compromising their transplant.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply to everyone. The drug switch might not improve tremors for all, and there is a risk of transplant rejection or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY PANCREAS TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Wisconsin
RECRUITINGMadison, Wisconsin, 53792, United States